

An AACR Special Conference on

# Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications

October 12-15, 2011  
The Fairmont San Francisco  
San Francisco, CA

## Wednesday, October 12

**7:00 p.m.-8:00 p.m.**      **Opening Keynote Address**  
*Chairperson: Jeffrey M. Rosen, Baylor College of Medicine,  
Houston, TX*

**Modeling breast cancer in three dimensions: Lessons learned**  
Joan S. Brugge, Harvard Medical School, Boston, MA

**8:00 p.m.-9:30 p.m.**      **Networking Reception**

## Thursday, October 13

**7:30 a.m.-8:30 a.m.**      **Continental Breakfast**

**8:30 a.m.-10:30 a.m.**      **Session 1**  
**Genomics/Epigenomics**  
*Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute,  
Boston, MA*

**Parity-associated changes in the human breast and their relevance to breast cancer**  
Kornelia Polyak

**Integrated molecular profiles of primary breast tumors: Improved prognostic power**  
Anne-Lise Børresen-Dale, Norwegian Radium Hospital, Institute for Cancer Research, Oslo,  
Norway

**Breast cancer epigenetics: From DNA methylation to noncoding RNAs**  
Manel Esteller, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

**Systems epigenomics for prognosis and personalized treatment**  
Tim Hui-Ming Huang, University of Texas Health Science Center in San Antonio, San Antonio,  
TX

**10:30 a.m.-11:00 a.m. Break**

**11:00 a.m.-12:30 p.m. Session 2  
Metabolomics**

*Chairperson: Lewis C. Cantley, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA*

**PI 3-kinase and cancer cell metabolism**

Lewis C. Cantley

**Nutrient addiction in the breast: Strong subtype-specific activities and potential therapeutic opportunities**

Luika Timmerman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

**Mechanisms involved in reduction in risk of breast cancer by metformin and similar compounds**

Michael Pollak, McGill University, Montreal, QC, Canada

**12:30 p.m.-2:30 p.m. Lunch on own**

**2:30 p.m.-4:30 p.m. Session 3  
Targeted Therapies (HER2, PIK3CA, Basal-like)**

*Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA*

Title to be announced

José Baselga

**Targeting IGF signaling in breast cancer subtypes**

Douglas Yee, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

**Targeting HER2: Current and future approaches**

Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA

**Basal-like breast cancer: What is the target?**

Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

**4:30 p.m.-7:00 p.m. Dinner on own**

**7:00 p.m.-10:00 p.m. Poster Session A/Reception**

## Friday, October 14

**7:30 a.m.-8:30 a.m. Continental Breakfast**

**8:30 a.m.-10:30 a.m. Session 4**  
**Inflammation and Cancer as Systemic Disease**  
*Chairperson: Patricia S. Steeg, National Cancer Institute, Bethesda, MD*

**The breast tumor microenvironment, tumor heterogeneity, and clinical outcome**  
 Morag Park, Canadian Institutes of Health Research, Montréal, QC, Canada

**Lymphocytes and the control of breast cancer metastasis**  
 Michael Karin, University of California San Diego, La Jolla, CA

**Tumor-entrained neutrophils inhibit seeding in the premetastatic lung**  
 Robert Benezra, Memorial Sloan-Kettering Cancer Center, New York, NY

**A LPA1 antagonist, Debio 0719, inhibits breast cancer metastasis and induces dormancy**  
 Patricia S. Steeg

**10:30 a.m.-11:00 a.m. Break**

**11:00 a.m.-12:30 p.m. Session 5**  
**Noncoding RNAs**  
*Chairperson: Jeffrey M. Rosen, Baylor College of Medicine, Houston, TX*

**Long noncoding RNAs in breast cancer progression**  
 Howard Y. Chang, Stanford University, Stanford, CA

**The role of noncoding RNA regulators of self renewal in cancer**  
 Michael F. Clarke, Stanford University School of Medicine, Palo Alto, CA

**The dodecalogus of noncoding RNAs involvement in breast cancer: 2011 version**  
 George A. Calin, University of Texas MD Anderson Cancer Center, Houston, TX

**12:30 p.m.-3:30 p.m. Poster Session B/Lunch**

**3:30 p.m.-5:00 p.m.**

**Session 6  
Stem Cells**

*Chairperson: Jeffrey M. Rosen, Baylor College of Medicine,  
Houston, TX*

**EMT programs and therapeutic resistance of breast cancer stem cells**

Jeffrey M. Rosen

**Phenotypic and functional characterization of the mammary luminal epithelial cell hierarchy**

John P. Stingl, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

**Mammary stem cell niche and implications for breast cancer**

Rama Khokha, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada

**5:00 p.m.-6:00 p.m.**

**Panel Discussion  
Transforming Translational Research: Innovation  
through Collaboration Between Women and Scientists**  
*Presented by The Love/Avon Army of Women*

**Panelists:**

Susan M. Love, Dr. Susan Love Research Foundation, Santa Monica, CA

Jennifer L. Ivanovich, Washington University School of Medicine, St. Louis, MO

Thea D. Tlsty, University of California School of Medicine, San Francisco, CA

Leslie Bernstein, City of Hope, Duarte, CA

**6:00 p.m.**

**Evening off / Dinner on own**

## Saturday, October 15

**7:30 a.m.-8:30 a.m. Continental Breakfast**

**8:30 a.m.-9:30 a.m. Keynote Address**

*Chairperson: Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA*

Title to be announced

Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY

**9:30 a.m.-10:00 a.m. Break**

**10:00 a.m.-11:30 a.m. Session 7  
Endocrine Resistance**

*Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA*

**Epigenetic and cistromic determinants of endocrine dependence**

Myles Brown, Dana-Farber Cancer Institute, Boston, MA

**Endocrine resistance: Insights from next-gen sequencing**

Matthew J. Ellis, Washington University Siteman Cancer Center, St. Louis, MO

**Escape pathways contributing to endocrine resistance in breast cancer**

C. Kent Osborne, Baylor College of Medicine Cancer Center, Houston, TX

**11:30 a.m. Departure**

